MX2019005742A - Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. - Google Patents

Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.

Info

Publication number
MX2019005742A
MX2019005742A MX2019005742A MX2019005742A MX2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A
Authority
MX
Mexico
Prior art keywords
formula
albumin
compound
pharmaceutically acceptable
binding psma
Prior art date
Application number
MX2019005742A
Other languages
English (en)
Inventor
Berkman Clifford
Choy Cindy
Original Assignee
Cancer Targeted Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Tech Llc filed Critical Cancer Targeted Tech Llc
Publication of MX2019005742A publication Critical patent/MX2019005742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con compuestos de la Fórmula (I) o una de sus sales farmacéuticamente aceptables, en donde L1 y L2 son cada uno independientemente un enlace covalente o un grupo de enlace divalente, R es un marcador detectable o un fármaco terapéutico y B es un radical de unión a albúmina. También se proporcionan composiciones que incluyen un compuesto de la Fórmula (I) junto con un vehículo farmacéuticamente aceptable, y métodos para obtener imágenes de células de cáncer de próstata usando un compuesto de Fórmula (I) .
MX2019005742A 2016-11-23 2017-11-24 Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. MX2019005742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (1)

Publication Number Publication Date
MX2019005742A true MX2019005742A (es) 2019-09-13

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005742A MX2019005742A (es) 2016-11-23 2017-11-24 Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.

Country Status (8)

Country Link
US (1) US11147889B2 (es)
EP (1) EP3544960A1 (es)
JP (1) JP7167021B2 (es)
CN (1) CN109982998A (es)
BR (1) BR112019010206A2 (es)
CA (1) CA3043619A1 (es)
MX (1) MX2019005742A (es)
WO (1) WO2018098390A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
US20220009883A1 (en) 2018-11-14 2022-01-13 Noria Therapeutics, Inc. Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020252598A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
EP4116306A4 (en) 2020-03-04 2024-05-29 Nihon Mediphysics Co Ltd COMPOUND AND RADIOACTIVE LABELING COMPOUND
CN116829541A (zh) * 2020-12-04 2023-09-29 加利福尼亚大学董事会 肽受体放射性核素治疗
EP4263509A1 (en) * 2020-12-16 2023-10-25 The University of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
KR20230154183A (ko) 2021-03-04 2023-11-07 니혼 메디피직스 가부시키가이샤 화합물 및 방사성 표지 화합물
WO2023164775A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority Radiolabeled compounds targetng the prostate-specific membrane antigen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
EP3964502A1 (en) * 2009-03-19 2022-03-09 The Johns Hopkins University Psma-targeting compounds and uses thereof
JP5843338B2 (ja) * 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
WO2013028664A1 (en) * 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
US20160257961A1 (en) * 2013-11-06 2016-09-08 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
CA2930581A1 (en) * 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
WO2016030329A1 (en) * 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
WO2017054907A1 (en) * 2015-09-30 2017-04-06 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
RU2749399C2 (ru) * 2016-03-22 2021-06-09 Дзе Джонс Хопкинс Юниверсити Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы
WO2017223357A1 (en) * 2016-06-23 2017-12-28 Cornell University Double targeted constructs to affect tumor kill
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Also Published As

Publication number Publication date
US20200061218A1 (en) 2020-02-27
CA3043619A1 (en) 2018-05-31
JP2019535754A (ja) 2019-12-12
BR112019010206A2 (pt) 2019-09-03
WO2018098390A1 (en) 2018-05-31
EP3544960A1 (en) 2019-10-02
US11147889B2 (en) 2021-10-19
CN109982998A (zh) 2019-07-05
JP7167021B2 (ja) 2022-11-08

Similar Documents

Publication Publication Date Title
MX2019005742A (es) Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
CY1125021T1 (el) Κιναζολινες ως αναστολεις διαυλων ιοντων καλιου
MX2018008168A (es) Inhibidores de antigenos de membrana especificos de la prostata (psma) basados en la urea para imaginologia y terapia.
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
CL2022001731A1 (es) Inhibidores de egfr.
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
CL2013000935A1 (es) Compuestos derivados de bencimidazol o sus sales, como inhibidores de cinasa pi3; composicion farmaceutica que los comprende; y su uso para el tratamiento de un neoplasma deficiente en pten seleccionado entre gliomas de cerebro, cancer de mama, cancer de prostata, cancer gastrico y mieloma multiple, entre otros.
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2011116299A3 (en) Myeloid derived suppressor cell inhibiting agents
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
UY38712A (es) Lactamas fusionadas de arilo y heteroarilo
PH12019502781A1 (en) Imidazole-containing inhibitors of alk2 kinase
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
SG10201407453TA (en) Kinase inhibitors
EA201270247A1 (ru) Способы применения с-мет-модуляторов
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
EP4335511A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
AU2017216846A8 (en) Pyrrolobenzodiazepine conjugates
TW201613938A (en) Selective inhibitors for protein kinases, a pharmaceutical composition and an use thereof
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa